|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Women with NAFLD had a higher BMI (P = 0.0002) and waist circumference (P = 0.0003), increased insulin resistance (P = 0.0004), and delayed suppression of glucagon after the OGTT (P < 0.0001), but NAFLD was not associated with the degree of glucose intolerance (P = 0.2196).
|
27810989 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
When assessing the five studies with the largest sample size, it clearly suggests a decreased GLP-1 response in IFG/IGT subjects.
|
29082261 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We investigated the association of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon levels are observed in subjects with impaired glucose tolerance (IGT).
|
27986831 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We demonstrated for the first time that single intragastric administration of 3DG resulted in acute reduction of incretin effect and glucose intolerance, which was associated with a decrease in the biological function of GLP-1 by decreasing GLP-1 secretion.
|
27658000 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vildagliptin suppressed an inappropriate glucagon response to an oral glucose challenge in patients with T2DM, to a mixed meal challenge in patients with T2DM and type 1 diabetes mellitus, and to a mixed meal challenge in subjects with IGT and IFG.
|
31781045 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (-5%), insulin resistance (-7%), glucose intolerance (-7%), glycated hemoglobin (-2%), glucagon (-6.5%), C-peptide (-5%), hsCRP (-12%), interleukin-6 (-13%), TNFα (-11%), lipid peroxidation (-17%), systolic blood pressure (-8%), GLP-1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%).
|
31183921 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To assess the effects of DPP-4 inhibitors and GLP-1 analogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these.
|
28489279 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, the postprandial GLP-1 response is not necessarily decreased but rather enhanced during obesity development, which is likely to play a protective role against glucose intolerance.
|
31636017 |
2020 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that GLP-1 normalizes the obesity-induced compensatory increase in β-cell mass and glucose intolerance through a neuronal relay system consisting of hepatic afferent nerves, the hypothalamus, and pancreatic efferent nerves.
|
28717164 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There was a weak relationship between the iAUC<sub>0-240 min</sub> for GIP and GLP-1 in the combined (r = 0.23, P = 0.015) and in the IGT (r = 0.34, P = 0.01), but not in the NGT (r = 0.15, P = 0.14) group.
|
31848710 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in α cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
|
28977595 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
|
28946907 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The potent and selective GLP-1-releasing effect of allulose holds promise for the prevention and treatment of glucose intolerance through promoting endogenous GLP-1 secretion.
|
29402406 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The increment of postprandial GLP-1 and insulinsecretion may have a role in normalizing postprandial glycaemia and slowing the establishment of glucose intolerance.
|
30878816 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The effect of incretin hormones to increase insulin release is reduced in ESRD which together with elevated glucagon levels could contribute to the high prevalence of IGT among ESRD patients.
|
31608934 |
2020 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E2) treatment.
|
29618657 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results indicate that high-glucose load leads to glucose intolerance with insulin resistance through impairment of GLP-1 secretion, increase of blood glucose levels via activating TLR4 and increasing levels of IL-6 and TNF-α in mice.
|
31138952 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
|
18080106 |
2008 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increasing secretion and production of glucagon-like peptide-1 (GLP-1) by continuous ingestion of certain food components has been expected to prevent glucose intolerance and obesity.
|
28161724 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition to impairment of glucose-induced insulin secretion, impaired glucagon-like peptide (GLP)1-induced insulin secretion has been identified to be present in subjects with diabetes and impaired glucose tolerance, but little is known about its fundamental mechanisms.
|
22928568 |
2012 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Improvement of reduced grooming behavior and normalization in reduced plasma insulin levels were seen only in 5M+2M Tg2576 mice while in 10M+2M Tg2576 mice oral galactose induced metabolic exacerbation at the level of plasma insulin, GLP-1 homeostasis and glucose intolerance, and additionally increased hippocampal sAβ1-42 level, decreased IR expression and increased GSK-3β activity.
|
30571958 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
|
16125528 |
2005 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hence, enhancing endogenous GLP-1 secretion by certain materials could be a potential target for prevention of glucose intolerance.
|
31352909 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ex9 impaired glucose tolerance in wild-type mice but had no impact on Gcg-null or GLP-1R KO mice, suggesting that Ex9 is a true and specific GLP-1R antagonist.
|
28325479 |
2017 |